XAGE Carmell Therapeutics Forward P/S Multiple

Carmell Therapeutics Corporation - graphic logo of issuer XAGE

The projected P/S of Longevity Health Holdings (XAGE) reflects the market valuation dynamics, where 3.90 represents the current level of the metric. Production is being automated through the implementation of robotic filling lines supervised by AI. Stable margins are ensured by high customer loyalty to plasma-based regeneration products. The premium positioning of biotechnological rejuvenation products allows the company to maintain high pricing power.

XAGE (carmellcosmetics.com) Price-to-Projected Revenue Ratio history from 04/04/2025 to 09/27/2025

Analytical breakdowns for Carmell Therapeutics (XAGE)

- current price and projected stock value:
Stock Price Carmell Therapeutics Corporation|XAGE - Analyst Target Range
- market capitalization data:
Market Capitalization Carmell Corp|XAGE - Total Enterprise Value
- issuer book value statistics:
Accounting Value per Share Longevity Health Holdings|XAGE - Company Book Value|Market Capitalization to Book Value Ratio carmellcosmetics.com|XAGE - Company Total Asset Base
- debt and liquidity data:
Total Debt to Equity Ratio Longevity Health Holdings|XAGE - Long-Term Loans to Capital Ratio|Short-Term Debt to Equity Ratio Carmell Corp|XAGE - Company Cumulative Debt|Debt to Book Value Carmell Therapeutics Corporation|XAGE - Company Long-Term Loans and Borrowings|Company Short-Term Debts Longevity Health Holdings|Quick Ratio carmellcosmetics.com
- net income and valuation multiples indicators:
XAGE - Company Net Income|Projected Future Earnings Longevity Health Holdings|XAGE - P/E Multiple|Future Price to Earnings Longevity Health Holdings|XAGE - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Carmell Corp|XAGE - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Longevity Health Holdings|XAGE - Earnings per share for the trailing year|Year-over-year net earnings per share growth for the last 12 months carmellcosmetics.com|XAGE - Earnings per share increase in current year|Earnings growth forecast for next year Longevity Health Holdings
- sales revenue and business income indicators:
XAGE - Company Sales Revenue|Company Projected Revenue carmellcosmetics.com|XAGE - Price to Sales|Price-to-Projected Revenue Ratio Carmell Therapeutics|XAGE - Sales Growth YoY (Last Twelve Months)
Initial company analysis:Longevity Health Holdings Inc (XAGE)
Manufactured products of carmellcosmetics.com

For Longevity Health Holdings (XAGE), the forward P/S valuation synthesizes market capitalization and expected sales volume, reflecting the dynamics of the business's fundamental re-rating. The growth of this indicator reflects market confidence in the expansion into aesthetic cosmetics; however, weak operational efficiency and high scaling costs leave the asset vulnerable to a sharp liquidity squeeze should revenue targets not be met.

Key competitors

Forward P/S Multiple HCA (HCA Healthcare, Inc.)|Price to Expected Revenue Ratio THC (Tenet Healthcare)|FMS - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio solventum.com|EHC: Forward P/S Multiple|UHS - Market Cap to Expected Sales Ratio|DVA (DaVita Corp) - Forward P/S Multiple|RDNT: Forward Price to Sales|Forward P/S Multiple OPCH|SGRY (surgerypartners.com) - Forward Price to Sales|Forward P/S Multiple PINC (Premier Inc)|National Vision - Price-to-Projected Revenue Ratio|PGNY - Price-to-Projected Revenue Ratio|ARDT - Forward P/S Multiple|SEM: Forward P/S Multiple|astranahealth.com (ASTH) - Forward P/S Multiple|MD (mednax.com) - Forward P/S Multiple|Forward P/S Multiple usph.com|Forward P/S Multiple PNTG|Market Cap to Expected Sales Ratio Organogenesis Holdings|Forward P/S Multiple NUTX (nutexhealth.com)|Auna SA (AUNA) - Market Cap to Future Revenue Ratio|SBC: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Jeuveau EOLS|CYH (Community Health Systems Inc) - Forward Price-to-Revenue Multiple|SKIN: Price to Expected Revenue Ratio|Forward Price-to-Revenue Multiple MDWD|BTMD: Forward Price to Sales|Price-to-Projected Revenue Ratio The Joint Corporation (JYNT)|Forward P/S Multiple DocGo Inc (DCGO)|Forward Price to Sales P3 Health Partners, Inc.|Market Cap to Expected Sales Ratio gaintherapeutics.com (GANX)|EUDA: Forward Price-to-Revenue Multiple|BMGL: Price-to-Projected Revenue Ratio|collplant.com (CLGN) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Cuprina Holdings|CCM (concordmedical.com) - Forward P/S Multiple|Forward P/S Multiple ASHS|Price-to-Projected Revenue Ratio MEDIROM (MRM)|ALBT - Market Cap to Future Revenue Ratio|DIH Holding US, Inc. - Forward Price-to-Revenue Multiple|NIVF: Market Cap to Projected Revenue|ATIP: Forward Price-to-Revenue Multiple|CareMax Medical Group - Price to Expected Revenue Ratio|Kindly MD (KDLY) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue MODV|Price-to-Projected Revenue Ratio Novo Integrated Sciences Corp|Market Cap to Future Revenue Ratio SunLink Health Systems SSY|Price-to-Projected Revenue Ratio IMAC Corp (BACK)